More pre-ASCO news:
Multiple Myeloma Research Consortium (MMRC) Announces Data Presentations at 46th Annual American Society of Clinical Oncology (ASCO) Annual Meeting
The Multiple Myeloma Research Consortium (MMRC) today announced the presentation of studies conducted through its clinical sites in collaboration with industry partners, Onyx Pharmaceuticals and Bristol-Myers Squibb, in evaluating promising new therapeutic agents for multiple myeloma at the 46th Annual American Society of Clinical Oncology (ASCO) Meeting, June 4-8, 2010 in Chicago, IL. The oral presentations will include updated data on MMRC-associated studies of potential drugs in the treatment of multiple myeloma.
“We are very excited to have data from these collaborative studies presented as part of the Clinical Science Symposium on Novel Therapies for Myeloma as well as the Oral Abstract Session at this year’s ASCO. These abstracts demonstrate the MMRC’s commitment to working side-by-side with its industry partners, and to implementing measures to enhance quality, speed and efficiency of clinical trials conducted by our Consortium clinical sites. We aim to ensure that promising new drug candidates are making progress in drug development since patients have needs for new therapeutic options,” said Susan Kelley, MD, Chief Medical Officer of the MMRC.
I will be interviewing Onyx Pharmaceutical’s Chief Medical Officer, Dr. Michael Kauffman, tomorrow at ASCO. Onyx makes the new novel therapy agent, carfilzomib. Any questions you would like me to ask Dr. Kauffman?
Feel good and keep smiling! Pat